Introduction {#Sec1}
============

Colorectal cancer (CRC) is one of the most common cancers worldwide. If the tumor is limited to the mucosa or submucosa, CRC can be completely cured by endoscopic or surgical therapy; however, many patients are already at an advanced stage when they are diagnosed. Therefore, an early detection method is needed. Diagnostic blood tests based on detection of carcinoembryonic antigen (CEA) are now widely used for CRC, but the sensitivity of this biomarker in early-stage cancer is only 5--10 % \[[@CR1], [@CR2]\]. The identification of novel candidate molecules that are secreted by cancer cells may lead to the development of early detection methods and improved prognosis.

Formalin-fixed and paraffin-embedded (FFPE) tissues are archived in hospitals, together with detailed clinical information such as disease history, clinical examination results, and drug responses. FFPE tissues are routinely used in the diagnosis and research of diseases, including cancers, by conventional staining, immunohistochemistry (IHC), and in situ hybridization \[[@CR3]--[@CR5]\]. Previously, FFPE tissues were considered unsuitable for proteomic analysis. However, methods to isolate protein from FFPE tissues for proteomic analysis have been developed, and various FFPE tissues have been used in proteomic studies \[[@CR6]--[@CR17]\]. Thus, archived FFPE tissues may be useful for identifying new biomarkers.

In this study, we performed shotgun liquid chromatography (LC)/mass spectrometry (MS)-based global proteomic analysis using proteins from FFPE CRC tissue to identify proteins whose expression levels are modified in cancer regions. We identified aldolase A as a candidate protein with potential as a novel biomarker for early detection of CRC.

Materials and methods {#Sec2}
=====================

Materials {#Sec3}
---------

The following materials were purchased from Wako Pure Chemical Industries (Osaka, Japan): guanidine hydrochloride, DTT, Tris, tris (2-carboxyethyl) phosphine hydrochloride (TCEP), and iodoacetamide (IAA). All other chemicals and reagents were purchased from Sigma Chemical Corp. (St. Louis, MO, USA).

Patients and tissue specimens {#Sec4}
-----------------------------

The tissues used in this study were from 45 patients who underwent surgical resection for CRC at Nippon Medical School Hospital between October 2007 and August 2014. None of the patients received chemotherapy or radiation therapy prior to surgery and none had inflammatory colorectal disease such as colitis or infectious diseases. The pathological diagnosis and clinicopathological stage were determined according to the criteria of the World Health Organization \[[@CR18]\]. After a histopathological analysis, 10 of these 45 cases were selected for proteomic analysis. Immunohistochemical analyses were performed on all 45 cases. Paraffin-embedded specimens were prepared for proteomic and immunohistochemical analyses. This study was carried out in accordance with the principles embodied in the Declaration of Helsinki, 2013, and the Japanese Society of Pathology Ethics Committee. Informed consent for the use of colorectal tissues was obtained from all patients.

Protein extraction from FFPE tissue {#Sec5}
-----------------------------------

FFPE CRC tissues from ten patients were used for proteomic analysis. Pathological and clinical information are shown in Table [1](#Tab1){ref-type="table"}. Following histological examination of hematoxylin and eosin (H&E) sections, we separated the cancer regions from the non-cancer regions, which maintained normal structures. Sections (10 μm) were deparaffinized in xylene and rehydrated through a series of graded alcohols (100, 90, 80, and 70 %). After staining with Mayer's hematoxylin for 5 min, cancer and non-cancer regions were manually dissected under a microscope (Fig. [1](#Fig1){ref-type="fig"}). Proteins were extracted from both cancer and non-cancer regions using lysis buffer (6 M guanidine-HCl, 40 mM Tris-HCl pH 8.2, and 65 mM DTT) according to a previous report \[[@CR17]\]. Protein concentration was measured by the Bradford method.Table 1Clinical and pathological data of patients with CRC that contributed tissues for proteomic analysisPatient No.Age (year)GenderpTNMpStagingTumor locationNumber of identified proteinsCancer regionNon-cancer region163MT3N0M0Stage IIAS4926253MT3N0M0Stage IIAS3838377FT3N0M0Stage IIAS5034453MT3N0M0Stage IIAS6952576FT3N0M0Stage IIAS5222651MT3N0M0Stage IIAA224767FTisN0M0Stage 0A4428852MT3N0M0Stage IIARa5250969MT3N0M0Stage IIAT65161069FT3N0M0Stage IIAS1935*M* male, *F* female, *A* ascending colon, *T* transverse colon, *S* sigmoid colon, *Ra* upper rectum Fig. 1Manual dissection of FFPE colon tissue. Representative image shows non-cancer and cancer regions before (**a** and **b**, respectively) and after (**c** and **d**, respectively) dissection. Sections were stained with hematoxylin

In-solution trypsin digestion {#Sec6}
-----------------------------

A gel-free digestion was performed according to the protocol described by Bluemlein et al. \[[@CR19]\], with slight modifications. Briefly, 10 μg of protein was extracted from each sample, reduced with 45 mM DTT and 20 mM TCEP, and then alkylated using 100 mM IAA. After alkylation, samples were digested with proteomics-grade trypsin (Agilent Technologies Inc., Santa Clara, CA, USA) at 37 °C for 24 h. Digests were purified using PepClean C-18 Spin Columns (Thermo, Rockford, IL, USA) according to the manufacturer's protocol.

LC-MS/MS analysis for protein identification {#Sec7}
--------------------------------------------

Approximately 2 μg of purified peptide samples were injected onto a peptide L-trap column (Chemicals Evaluation and Research Institute, Tokyo, Japan) using an HTS PAL autosampler (CTC Analytics, Zwingen, Switzerland) and further separated thorough an Advance-nano UHPLC (AMR Inc., Tokyo, Japan) using a reverse-phase C18-column (Zaplous column α, 3-μm diameter gel particles and 100 Å pore size, 0.1 × 150 mm; AMR). The mobile phase consisted of solution A (0.1 % formic acid in water) and solution B (acetonitrile). The flow rate was 500 nL/min, with a concentration gradient of acetonitrile from 5 % B to 35 % B over 120 min. Gradient-eluted peptides were analyzed using an amaZon ETD ion-trap mass spectrometer (Bruker Daltonics, Billerica, MA, USA). Data were acquired in a data-dependent manner, in which MS/MS fragmentation was performed on the ten most intense peaks of every full MS scan.

All MS/MS spectra data were searched against the SwissProt *Homo sapiens* database with Mascot (version_2.3.01; Matrix Science, London, UK). Search criteria were as follows: enzyme, trypsin; allowance of up to two missed cleavage peptides; mass tolerance ±0.5 Da and MS/MS tolerance ±0.5 Da; and modifications of cysteine carbamidomethylation, methionine oxidation, and N-formylation including formyl (K), formyl (R), and formyl (N terminus).

Spectral counting analysis of identified proteins {#Sec8}
-------------------------------------------------

To compare protein expression across all tissue samples, we used the spectral counting method. In this analysis, when not specific spectral peak could be identified, the expression level of that protein was taken as zero, as described in a previous report \[[@CR20]\]. Fold-changes of expressed proteins in the base 2 logarithmic scale were calculated with Rsc based upon spectral counting \[[@CR21]\]. Relative amounts of identified proteins were also calculated with the normalized spectral abundance factor (NSAF) \[[@CR22]\]. Candidate proteins with modified expression levels in the cancer region were chosen to ensure that the Rsc satisfied \>1 or \<−1, which corresponded to fold changes of \>2 or \<0.5.

Bioinformatics {#Sec9}
--------------

Functional annotations for the identified proteins with modified expression levels in the cancer region were processed using the Database for annotation, visualization, and integrated discovery (DAVID) version 6.7 (<http://david.abcc.ncifcrf.gov/home.jsp>) \[[@CR23]--[@CR25]\].

Quantitative RT-PCR {#Sec10}
-------------------

Total RNA was extracted from FFPE CRC tissue with the RNeasy FFPE Kit (QIAGEN, Valencia, CA, USA) and from CRC cell lines with the GenElute Mammalian Total RNA Miniprep Kit (Sigma). cDNA was synthesized using the SuperScript VILO cDNA Synthesis Kit for FFPE tissue and the High Capacity cDNA Reverse Transcription kit for the CRC cell line according to the manufacturer's protocols (Life Technologies Japan, Tokyo, Japan). To measure expression of aldolase A, cyclophilin A, and annexin A2 mRNA, quantitative reverse transcription PCR (qRT-PCR) was performed with the 7500 system (Applied Biosystems, Foster City, CA, USA). Primers and TaqMan probes for aldolase A (Hs00765620_m1), cyclophilin A (Hs04194521_s1), annexin A2 (Hs00743063_s1), and 18S rRNA (Hs03928990_g1) were used with the TaqMan Gene Expression Assay. qRT-PCR results were expressed relative to an internal standard concentration as a ratio of target/18S rRNA. Gene expression was measured in triplicate.

Immunohistochemistry {#Sec11}
--------------------

FFPE CRC tissues from 46 patients were used for a validation analysis. Pathological and clinical information are shown in Table [2](#Tab2){ref-type="table"}. Paraffin-embedded tissue sections (3 μm) were subjected to immunostaining using a Histofine Simple Stain MAX-PO (R) kit (Nichirei, Tokyo, Japan) for identifying aldolase A, annexin A2, and cyclophilin A. After deparaffinization, sections were pretreated in an autoclave at 121 °C for 15 min in 10 mM citrate buffer (pH 6.0) for cyclophilin A. Endogenous peroxidase activity was blocked by incubation for 30 min with 0.3 % hydrogen peroxide in methanol. Tissue sections were then incubated with the anti-ALDOA antibody (1:150 dilution; Atlas Antibodies, Stockholm, Sweden) for aldolase A, anti-cyclophilin A antibody (1:150 dilution; Novus Biologicals, Littleton, CO, USA), or anti-annexin A2 antibody (1:400 dilution; Cell Signaling Technology, Inc., Danvers, MA, USA) in phosphate-buffered saline containing 1 % bovine serum albumin for 16 h at 4 °C. Bound antibodies were detected with the Simple Stain MAX-PO (R) with diaminobenzidine tetrahydrochloride as the substrate. Sections were then counterstained with Mayer's hematoxylin. Two investigators (TY and HT) evaluated all the sections separately in a blinded manner. Sections were scored for both intensity (0, no stain; 1, weak; 2, moderate; and 3, strong) and percentage of epithelial cells that stained positive (0, 0--5 %; 1, 6--25 %; 2, 26--50 %; 3, 51--75 %; and 4, 76--100 %). Scores were derived from the sum of the intensity and percentage of immunoreactive cells \[[@CR15]\].Table 2Clinical and pathological data of patients with CRC that contributed tissues for immunohistochemical analysisPatient No.Age(year)GenderpTNMpStagingTumor location167FTisN0M0Stage 0A266FTisN0M0Stage 0D361FTisN0M0Stage 0S470MTisN0M0Stage 0T564FTisN0M0Stage 0T663MT2N0M0Stage IRb758FT2N0M0Stage IRb845FT2N0M0Stage IRb967FT2N0M0Stage IRa1087FT2N0M0Stage IRa1167FT2N0M0Stage IS1270MT1N0M0Stage IS1375FT1N0M0Stage IT1482MT1N0M0Stage IT1563MT3N0M0Stage IIAS1653MT3N0M0Stage IIAS1777FT3N0M0Stage IIAS1853MT3N0M0Stage IIAS1976FT3N0M0Stage IIAS2051MT3N0M0Stage IIAA2152MT3N0M0Stage IIARa2269MT3N0M0Stage IIAT2369FT3N0M0Stage IIAS2492MT3N0M0Stage IIAT2564MT2N1aM0Stage IIIARa2673FT2N1bM0Stage IIIARa2764MT3N1aM0Stage IIIBRa2850FT3N1bM0Stage IIIBS2951MT3N1bM0Stage IIIBA3064MT3N1aM0Stage IIIBS3164FT3N1bM0Stage IIIBRa3278FT3N1aM0Stage IIIBA3372FT4aN1AM0Stage IIIBC3452MT3N1bM0Stage IIIBRa3585FT4bN1aM0Stage IIICA3670MT4aN2aM0Stage IIICS3781FT4aN0M1aStage IVAT3871FT4aN2aM1aStage IVAA3949MT3N2aM1aStage IVAC4078MT3N1bM1aStage IVARa4177MT4aN2aM1aStage IVAT4257MT3N2bM1bStage IVBRa4372FT4aN0M1bStage IVBD4471FT4bN2bM1bStage IVBC4570MT3N0M1bStage IVBS*M* male, *F* female, *A* ascending colon, *T* transverse colon, *S* sigmoid colon, *Ra* upper rectum, *Rb* lower rectum, *D* descending colon, *C* cecum

CRC cell lines {#Sec12}
--------------

CRC cell lines DLD-1, SW480, and SW620 and normal human colon epithelial cell line CCD 841 CoN were purchased from the American Type Culture Collection (Manassas, VA, USA). All cells were cultured in RPMI 1640 medium supplemented with 10 % fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA) in an atmosphere containing 5 % CO~2~.

Protein preparation {#Sec13}
-------------------

CRC cells were plated at a density of 5 × 10^5^ cells per dish in a 100-mm dish and grown in culture medium. After 72 h, cells were solubilized in urea lysis buffer (7 M urea, 2 M thiourea, 5 % CHAPS, and 1 % Triton X-100). To quantify secreted protein, the culture medium of CRC cells was collected after 72 h.

Western blot analysis {#Sec14}
---------------------

The cell extract, culture medium, and commercial human normal serum (ImmunoBioScience Corp., Mukilteo, WA) were subjected to SDS-PAGE under reducing conditions. The separated proteins were transferred to polyvinylidene fluoride transfer membranes. Membranes were incubated with an anti-annexin A2 rabbit monoclonal antibody, anti-aldolase A rabbit monoclonal antibody, or anti-cyclophilin A antibody (Cell Signaling Technology Inc., Beverly, MA, USA) at 4 °C overnight. Membranes were then washed and incubated with HRP-conjugated anti-rabbit IgG antibody (American Qualex, San Clemente, CA). After washing, blots were visualized by enhanced chemiluminescence and detected using a myECL Imager system (ThermoFisher Scientific). The same membranes were reprobed with anti-β-actin antibody (Sigma) to confirm equal loading of the proteins. All Western blot analyses were performed three times.

Statistical analysis {#Sec15}
--------------------

All data are presented as the mean ± standard error of the mean. Data between two groups were compared with the unpaired *t* test. Values of \**P* \< 0.05 and \*\**P* \< 0.001 were considered significant in all analyses. Computations were performed with GraphPad Prism version 5 (GraphPad Software, La Jolla, CA, USA).

Results {#Sec16}
=======

Protein identification and profiles in cancer and non-cancer regions of CRC tissue {#Sec17}
----------------------------------------------------------------------------------

To investigate the molecular profile of proteins expressed in relation to cancer progression, we performed shotgun proteomic analysis using FFPE CRC tissue. We used manual dissection to separate the cancer regions and non-cancer regions from FFPE CRC tissues and examined the protein expression not only in cells but also in the stromal tissue surrounding cells (Fig. [1](#Fig1){ref-type="fig"}). We successfully identified proteins in both cancer and non-cancer regions of FFPE tissues (Table [1](#Tab1){ref-type="table"}). Figure [2](#Fig2){ref-type="fig"} shows the Venn map for the proteins identified.Fig. 2Venn map of proteins identified from FFPE colorectal cancer tissue. We identified 204 proteins in the cancer regions and 142 in the non-cancer regions

Semiquantitative comparison of proteins identified in cancer and non-cancer regions of CRC tissue {#Sec18}
-------------------------------------------------------------------------------------------------

We next performed a label-free semiquantitative method based on spectral counting to identify proteins with modified expression levels in the cancer region. The Rsc value was plotted against the corresponding protein (*x*-axis) in increasing order from left to right for proteins identified in the cancer and non-cancer regions. Positive and negative Rsc values indicate increased and decreased expression, respectively, in the cancer region. In Fig. [3](#Fig3){ref-type="fig"}, the NSAF value (bar) was plotted against the corresponding protein (*x*-axis) and the NSAF values of the cancer regions (black bar) and non-cancer regions (gray bar). Proteins are indicated above and below the *x*-axis. Proteins with either a high positive or negative Rsc value were considered as potential early detection markers for CRC.Fig. 3Semiquantitative comparison of proteins identified in FFPE colon tissue. Rsc and normalized spectral abundance factor (NSAF) values calculated for the proteins identified (*x*-axis). Comparison of protein expression in cancer versus non-cancer tissue. Proteins highly expressed in either cancer or non-cancer regions were plotted near the right or left side of the *x*-axis

A total of 84 differentially expressed proteins were identified in the cancer regions (Table [3](#Tab3){ref-type="table"}). Representative proteins that were upregulated included known tumor markers such as 60 kDa heat shock protein (HSP60) and carcinoembryonic antigen-related cell adhesion molecule 5 (CEAM5, also known as CEA). By contrast, expression levels of housekeeping proteins such as β-actin and histone H4 did not change.Table 3Differentially expressed proteins in cancer region of CRC samplesNo.IDAccession number and descriptionNo. of amino acidsSpectral countingNon-cancerCancerFold change (Rsc)1FCGBP_HUMAN(Q9Y6R7) IgGFc-binding protein5405151−3.3070862K1C10_HUMAN(P13645) Keratin, type I cytoskeletal 1058470−3.1634093H3C_HUMAN(Q6NXT2) Histone H3.3C135121−3.0069644CO1A1_HUMAN(P02452) Collagen alpha-1(I) chain146460−2.9751215K22E_HUMAN(P35908) Keratin, type II cytoskeletal 2 epidermal63950−2.7591256K2C6B_HUMAN(P04259) Keratin, type II cytoskeletal 6B56450−2.7591257H2B1A_HUMAN(Q96A08) Histone H2B type 1-A12791−2.6309438K1C14_HUMAN(P02533) Keratin, type I cytoskeletal 1447240−2.5057179K1C17_HUMAN(Q04695) Keratin, type I cytoskeletal 1743240−2.50571710K2C5_HUMAN(P13647) Keratin, type II cytoskeletal 559040−2.50571711CRIP1_HUMAN(P50238) Cysteine-rich protein 17730−2.19899512MUC2_HUMAN(Q02817) Mucin-2517930−2.19899513ATPA_HUMAN(P25705) ATP synthase subunit alpha, mitochondrial55361−2.12574214K2C1B_HUMAN(Q7Z794) Keratin, type II cytoskeletal 1b578134−1.88727515LMNA_HUMAN(P02545) Prelamin-A/C664103−1.8468216K1C9_HUMAN(P35527) Keratin, type I cytoskeletal 9623155−1.82761217ACTN4_HUMAN(O43707) Alpha-actinin-491120−1.81010718GLUC_HUMAN(P01275) Glucagon18020−1.81010719RS7_HUMAN(P62081) 40S ribosomal protein S719420−1.81010720K2C1_HUMAN(P04264) Keratin, type II cytoskeletal 16443918−1.54128721CLCA1_HUMAN(A8K7I4) Calcium-activated chloride channel regulator 191473−1.39372322CAH1_HUMAN(P00915) Carbonic anhydrase 126110−1.27773123GSLG1_HUMAN(Q92896) Golgi apparatus protein 1117910−1.27773124LAMB3_HUMAN(Q13751) Laminin subunit beta-3117210−1.27773125MK15_HUMAN(Q8TD08) Mitogen-activated protein kinase 1554410−1.27773126RS30_HUMAN(P62861) 40S ribosomal protein S305910−1.27773127ZHANG_HUMAN(Q9NS37) CREB/ATF bZIP transcription factor35410−1.27773128ZN408_HUMAN(Q9H9D4) Zinc finger protein 40872010−1.27773129PGBM_HUMAN(P98160) Basement membrane-specific heparan sulfate proteoglycan core protein439110−1.27773130DPYL2_HUMAN(Q16555) Dihydropyrimidinase-related protein 257210−1.27773131RL31_HUMAN(P62899) 60S ribosomal protein L3112510−1.27773132HNRPL_HUMAN(P14866) Heterogeneous nuclear ribonucleoprotein L58910−1.27773133FLNA_HUMAN(P21333) Filamin-A264710−1.27773134CO6A2_HUMAN(P12110) Collagen alpha-2(VI) chain101910−1.27773135ARPC5_HUMAN(O15511) Actin-related protein 2/3 complex subunit 515110−1.27773136RS23_HUMAN(P62266) 40S ribosomal protein S2314310−1.27773137MYH14_HUMAN(Q7Z406) Myosin-14199510−1.27773138EF2_HUMAN(P13639) Elongation factor 285810−1.27773139ECHB_HUMAN(P55084) Trifunctional enzyme subunit beta, mitochondrial47410−1.27773140FA48A_HUMAN(Q8NEM7) Protein FAM48A77910−1.27773141SETX_HUMAN(Q7Z333) Probable helicase senataxin267710−1.27773142GFAP_HUMAN(P14136) Glial fibrillary acidic protein43210−1.27773143PERI_HUMAN(P41219) Peripherin47010−1.27773144POTEE_HUMAN(Q6S8J3) POTE ankyrin domain family member E107510−1.27773145TTHY_HUMAN(P02766) Transthyretin14710−1.27773146CAH2_HUMAN(P00918) Carbonic anhydrase 226010−1.27773147ENPL_HUMAN(P14625) Endoplasmin80310−1.27773148HS71L_HUMAN(P34931) Heat shock 70 kDa protein 1-like64110−1.27773149CBR1_HUMAN(P16152) Carbonyl reductase \[NADPH\] 127710−1.27773150SPTA2_HUMAN(Q13813) Spectrin alpha chain, brain247210−1.27773151HNRCL_HUMAN(O60812) Heterogeneous nuclear ribonucleoprotein C-like 129310−1.27773152UGGG1_HUMAN(Q9NYU2) UDP-glucose:glycoprotein glucosyltransferase 1155510−1.27773153OST48_HUMAN(P39656) Dolichyl-diphosphooligosaccharide\--protein glycosyltransferase 48 kDa subunit45610−1.27773154ACTA_HUMAN(P62736) Actin, aortic smooth muscle3774023−1.23847855AGR2_HUMAN(O95994) Anterior gradient protein 2 homolog17542−1.12443956TBB2C_HUMAN(P68371) Tubulin beta-2C chain445127−1.12417357KCRB_HUMAN(P12277) Creatine kinase B-type38185−1.00149258HSP7C_HUMAN(P11142) Heat shock cognate 71 kDa protein643151.05112259PPIA_HUMAN(P62937) Peptidyl-prolyl cis-trans isomerase A165151.05112260SBP1_HUMAN(Q13228) Selenium-binding protein 1472151.05112261G3P_HUMAN(P04406) Glyceraldehyde-3-phosphate dehydrogenase3356191.069291962ANXA2_HUMAN(P07355) Annexin A2339161.266635663MDHM_HUMAN(P40926) Malate dehydrogenase, mitochondrial338161.266635664ALDOA_HUMAN(P04075) Fructose-bisphosphate aldolase A364031.341811565LDHA_HUMAN(P00338) L-lactate dehydrogenase A chain332031.341811566RL7_HUMAN(P18124) 60S ribosomal protein L7248031.341811567S10A8_HUMAN(P05109) Protein S100-A893031.341811568RL12_HUMAN(P30050) 60S ribosomal protein L12165031.341811569TBB1_HUMAN(Q9H4B7) Tubulin beta-1 chain451031.341811570TAGL2_HUMAN(P37802) Transgelin-2199031.341811571LDHA_HUMAN(P00338) L-lactate dehydrogenase A chain332031.341811572DHSA_HUMAN(P31040) Succinate dehydrogenase \[ubiquinone\] flavoprotein subunit, mitochondrial664031.341811573S10A9_HUMAN(P06702) Protein S100-A9114031.341811574TBA1A_HUMAN(Q71U36) Tubulin alpha-1 A chain451031.341811575FIBA_HUMAN(P02671) Fibrinogen alpha chain866041.648052376CEAM5_HUMAN(P06731) Carcinoembryonic antigen-related cell adhesion molecule 5702041.648052377RL1D1_HUMAN(O76021) Ribosomal L1 domain-containing protein 1490041.6480523781433B_HUMAN(P31946) 14--3-3 protein beta/alpha246051.900978679ACTN1_HUMAN(P12814) Alpha-actinin-18921101.906076780DEF1_HUMAN(P59665) Neutrophil defensin 1941132.251304481CH60_HUMAN(P10809) 60 kDa heat shock protein, mitochondrial5732232.500008482H2B1C_HUMAN(P62807) Histone H2B type 1-C/E/F/G/I126092.62023883H31_HUMAN(P68431) Histone H3.11360133.101161184TBB5_HUMAN(P07437) Tubulin beta chain4440133.1011611Expression levels of these 84 proteins were more than two-fold higher or lower in cancer regions compared to non-cancer regions of CRC samples

Functional annotation of differentially expressed proteins in cancer regions of CRC tissue {#Sec19}
------------------------------------------------------------------------------------------

DAVID was used to perform GO analyses for the differentially expressed proteins identified for each cellular component (Fig. [4](#Fig4){ref-type="fig"}). Functional annotations were counted by normalizing to the total number of identified proteins. Based on the cellular component classification, we focused on 21 proteins classified in the extracellular region, which could potentially be detected in the blood of patients with CRC (Table [4](#Tab4){ref-type="table"}).Fig. 4Analysis of GO cellular components of identified proteins. Protein assignments to GO cellular component categories are shown only for significant categories (*p* \< 0.05) Table 4Proteins categorized as extracellular region proteinsNo.Accession number and descriptionFold change (Rsc)1(Q9Y6R7) IgGFc-binding protein−3.30708552(P02452) Collagen alpha-1(I) chain−2.97512143(Q02817) Mucin-2−2.19899514(O43707) Alpha-actinin-4−1.81010745(P01275) Glucagon−1.81010746(A8K7I4) Calcium-activated chloride channel regulator 1−1.39372337(Q13751) Laminin subunit beta-3−1.27773058(Q8TD08) Mitogen-activated protein kinase 15−1.27773059(P98160) Basement membrane-specific heparan sulfate proteoglycan core protein−1.277730510(P21333) Filamin-A−1.277730511(P12110) Collagen alpha-2(VI) chain−1.277730512(P02766) Transthyretin−1.277730513(P00918) Carbonic anhydrase 2−1.277730514(O95994) Anterior gradient protein 2 homolog−1.124439215(P62937) Peptidyl-prolyl cis-trans isomerase A1.0511219716(P07355) Annexin A21.2666356517(P04075) Fructose-bisphosphate aldolase A1.3418115218(P02671) Fibrinogen alpha chain1.6480523119(P12814) Alpha-actinin-11.9060766620(P59665) Neutrophil defensin 12.2513044221(P10809) 60 kDa heat shock protein, mitochondrial2.50000843Twenty-one proteins that were differentially expressed in cancer regions of CRC samples were classified as extracellular region proteins by gene ontology analysis

qRT-PCR analysis of aldolase A, cyclophilin A, and annexin A2 in cancer and non-cancer regions of CRC tissue {#Sec20}
------------------------------------------------------------------------------------------------------------

Fructose-bisphosphate aldolase A (aldolase A), peptidyl-prolyl cis-trans isomerase A (also known as cyclophilin A), and annexin A2 were upregulated in cancer regions (Table [3](#Tab3){ref-type="table"}) and consequently selected as candidate diagnostic biomarkers. To confirm the higher expression levels of the candidate proteins in cancer regions compared to non-cancer regions, we performed qRT-PCR analysis. Expression levels of the mRNAs for these proteins were significantly higher in cancer compared to non-cancer regions (Fig. [5](#Fig5){ref-type="fig"}a--c).Fig. 5qPCR analysis of spectral counting results. Aldolase A, cyclophilin A, and annexin A2 were selected for confirmation. Expression levels of aldolase A, cyclophilin A, and annexin A2 mRNA were significantly higher in cancer compared to non-cancer regions (**a**--**c**). \**p* \< 0.05, \*\**p* \< 0.001

IHC analysis of aldolase A, cyclophilin A, and annexin A2 in cancer and non-cancer regions of CRC tissue {#Sec21}
--------------------------------------------------------------------------------------------------------

We next performed IHC analysis of the three candidate proteins for validation with tissues from 45 CRC cases (Table [2](#Tab2){ref-type="table"}). IHC analysis revealed that expression levels of all three proteins were significantly higher in cancer regions compared to non-cancer regions (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6IHC validation of spectral counting results. Expression levels of aldolase A, cyclophilin A, and annexin A2 were validated by IHC. Representative images of non-cancer regions (**a**, **d**, and **g**) and cancer regions (**b**, **e**, and **h**). Graphs of IHC scores are shown in (**c**), (**f**), and (**i**). Cancer regions showed significantly stronger expression of these three proteins, which is consistent with spectral counting data. \**p* \< 0.05; \*\**p* \< 0.001. Original magnification, 100×; insets, 400×

Expression of aldolase A, cyclophilin A, and annexin A2 in CRC cell lines {#Sec22}
-------------------------------------------------------------------------

To investigate whether the candidate proteins were suitable as biomarkers, their mRNA and protein expression levels in CRC cell lines were determined by qRT-PCR analysis and western blotting. All tested cell lines expressed the three candidate proteins, and their expression levels in CRC cells tended to be higher than in normal colon epithelial cells (Fig. [7](#Fig7){ref-type="fig"}a--d). Aldolase A was not detected in the culture medium of the three CRC cell lines, but it was detected in normal colon epithelial cells (Fig. [7](#Fig7){ref-type="fig"}e, upper panel). Cyclophilin A was not detected in the culture medium of any cell lines (Fig. [7](#Fig7){ref-type="fig"}e, middle panel). The level of annexin A2 in the culture medium appeared to depend on the level of annexin A2 in the cell extract for each cell line (Fig. [7](#Fig7){ref-type="fig"}e, lower panel). Finally, we detected aldolase A in normal human serum and confirmed that the level depended on the loaded serum volume (Fig. [7](#Fig7){ref-type="fig"}f, lane 1--3).Fig. 7Expression of the three candidate proteins in CRC cell lines. Expression levels of aldolase A, cyclophilin A, and annexin A2 were examined by qRT-PCR and western blot. Expression levels of aldolase A (**a**), cyclophilin A (**b**), and annexin A2 (**c**) mRNA in CRC cells were almost all significantly higher than in normal colon epithelium. \**p* \< 0.05; \*\**p* \< 0.001. Expression levels of the three candidate proteins in cell extracts from CRC cell lines were similar to mRNA expression levels (**d**). Aldolase A was only detected in the culture medium of normal colon epithelium (**e**, upper panel). Cyclophilin A was not detected in any of the examined culture medium samples (**e**, middle panel). The level of annexin A2 in the culture medium appeared to depend on the level in the cell extract for each cell line (**e**, lower panel). Aldolase A was detected in human normal serum, and the level of aldolase A detected depended on the volume of serum loaded (**f**, lane 1, 10 μg serum; lane 2, 20 μg serum; lane 3, 30 μg serum)

Discussion {#Sec23}
==========

In this study, we used a gel-free LC-MS-based proteomics approach to identify potential biomarkers for cancer in FFPE CRC tissues. We used semiquantitative methods based on spectral counting to detect 84 proteins in which expression levels were altered \>2-fold in cancer compared to non-cancer regions of CRC tissue (Table [3](#Tab3){ref-type="table"}). CEA, a known tumor marker used in diagnostic blood tests for CRC, was among these proteins. Thus, the approach used in this study could potentially be used to identify novel biomarker candidates.

To identify early detection markers for CRC that can be detected by diagnostic blood tests, we focused on proteins in the "extracellular region" category of cellular components based on the results of GO analysis (Table [4](#Tab4){ref-type="table"}). These proteins are secreted into the extracellular space and thus may potentially be detected in blood. These criteria led us to select aldolase A, cyclophilin A, and annexin A2 as candidates. We did not include HSP60, neutrophil defensin1, or alpha-actinin-1, because previous reports had already suggested that these proteins might be biomarkers for CRC \[[@CR26]--[@CR29]\].

Validation studies revealed that mRNA and protein expression levels of the three candidate proteins were significantly higher in the cancer region compared to non-cancer regions (Figs. [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"}). Moreover, to evaluate whether these proteins were useful as biomarkers, we also investigated their mRNA and protein expression levels in CRC cell lines and secretion of the proteins into the medium. Cyclophilin A was not secreted into the culture medium of all tested CRC cell lines (Fig. [7](#Fig7){ref-type="fig"}e). Thus, cyclophilin A is not suitable as a diagnostic blood tumor marker. On the other hand, annexin A2 expression in SW480 cells derived from the primary tumor site of a CRC patient was higher than expression in SW620 cells that were established from a metastatic site in the same patient (Fig. [7](#Fig7){ref-type="fig"}c--e). Decreased annexin A2 expression in cancer cells could play a role in the progression and metastasis of CRC and may be useful for predicting metastasis.

Although mRNA and protein expression of aldolase A were detected in all tested cell lines (Fig. [7](#Fig7){ref-type="fig"}a and d), aldolase A protein was not detected in the culture medium of the three CRC cell lines, while it was clearly detected in the culture medium of normal colon epithelial cells (Fig. [7](#Fig7){ref-type="fig"}e). Moreover, aldolase A was detected in normal human serum (Fig. [7](#Fig7){ref-type="fig"}f). These results suggest that secretion of aldolase A may be suppressed by dysfunction of aldolase A due to accumulated genetic mutations during the carcinogenesis process of CRC. Therefore, decreased aldolase A levels in blood may be useful as a biomarker for the early diagnosis of CRC.

Aldolase A is a glycolytic enzyme and contributes to various cellular functions related to muscle maintenance, cell shape and mobility regulation, striated muscle contraction, actin filament organization, and ATP biosynthesis \[[@CR30]--[@CR40]\]. There are several reports of elevated expression of aldolase A in the serum of patients with malignant tumors, such as those with lung and renal cancer \[[@CR41], [@CR42]\]. However, the expression kinetics and functions of aldolase A in CRC are not well understood. To our knowledge, this is the first report of decreased secretion of aldolase A in CRC. Thus, further studies are necessary to clarify the decrease in aldolase A levels in the blood of CRC patients in order to determine if this protein can be used as an early detection biomarker for CRC.

Conclusion {#Sec24}
==========

In conclusion, we identified 248 proteins from FFPE CRC tissues using global shotgun proteomics. A label-free semiquantitative method based on spectral counting and GO identified 21 candidate early detection biomarkers for CRC that could potentially be detected in blood. Validation studies revealed that cyclophilin A, annexin A2, and aldolase A expression levels were significantly higher in cancer compared to non-cancer regions. In vitro studies showed that secretion of aldolase A into the culture medium was clearly suppressed in CRC cancer cells to normal colon epithelium. Finally, aldolase A may play an important role in the carcinogenesis process of CRC and may be useful as an early detection biomarker for CRC.
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